에 대한 최신 뉴스 Truist Finl (NYSE:TFC) 주식

Truist Finl

Based in Charlotte, North Carolina, Truist is the combination of BB&T and SunTrust. Truist is a regional bank with a presence primarily in the Southeastern United States. In addition to commercial banking, retail banking, and investment banking operations, the company operates several nonbank segments.

banks-ai3

Opinion

Trading Ideas

지역 은행 부문은 지난 2년 동안 잘못된 이유로 많은 헤드라인을 장식했다. 실리콘밸리 은행, 시그니처 은행 및 퍼스트 리퍼블릭 은행과 같은 은행 파산 사건은 이 부문에 큰 충격을 주었고, 2023년 말 SPDR 지역은행 ETF(NYSE:KRE)는 40% 이상 하락했다.

트럼프가 증권거래위원회 새 리더십을 지명하기 전에 사야 할 6개 지역 은행주

Earnings

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Small Cap

Econ #s

Economics

ETFs

COLB

FCNCA

FITB

PNFP

WTFC

미국 은행들의 3분기 실적 발표 시즌이 이번 금요일에 공식적으로 시작된다. JP모건 체이스(NYSE:JPM), 웰스 파고(NYSE:WFC) 및 뉴욕 멜론 은행(NYSE:BK)과 같은 주요 금융 기관들이 실적을 발표할 예정이다.

美 은행들, 실적 시즌 준비: 씨티그룹, 모건 스탠리, 트루이스트 등 15개의 주식 추천

banks ai

Equities

Broad U.S. Equity ETFs

Federal Reserve

TCBI

미국 은행들이 3분기 실적을 발표할 준비를 하면서, 투자자들은 경제의 연착륙 가능성, 연방준비제도(연준)의 금리 인하, 그리고 이들이 은행 가치 평가에 미치는 영향에 주목하고 있다.

미국 은행 실적 미리보기: 연착륙 희망, 금리 인하, 주가의 주요 촉매제

Truist Financial Corporation Common Stock

Truist Financial Corp

Terra Firma Capital Corp

Truist Financial Corporation Depositary Shares

Truist Financial Corporation Depositary Shares, Each Representing a 1/1,000th Interest in a Share of Series O Non-Cumulative Perpetual Preferred Stock

Truist Financial Corporation Depositary Shares, each representing 1/1,000th interest in a share of Series R Non-Cumulative Perpetual Preferred Stock

AbbVie (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), a biopharmaceutical company, is engaged in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide.
It will report its Q1 2025 earnings on April 25, before the market opens. Wall Street analysts expect the company to post EPS of $2.51, up from $2.31 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expected to be $12.91 billion, up from $12.31 billion a year earlier.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a></li>
</ul>
The 52-week range of AbbVie stock price was $153.58 to $218.66.
AbbVie's dividend yield is 3.86%. It paid $6.56 per share in dividends during the last 12 months.
<h2 class="wp-block-heading">The Latest On AbbVie</h2>
On Jan. 31, the company announced its Q4 2024 earnings, posting adjusted EPS of $2.16, beating the street view of $2.11, as reported by <a href="https://www.benzinga.com/news/earnings/25/01/43392796/abbvie-jumps-after-q4-earnings-beat-skyrizi-and-rinvoq-boom-offsets-humira-decline">Benzinga</a>. Quarterly sales came in at $15.102 billion, outpacing the analyst consensus estimate of $14.827 billion.&nbsp;
AbbVie sees full-year 2025 adjusted EPS in the range of $12.12 to $12.32, compared to the street view of $12.18. The company reaffirmed its expectations for a high single-digit compound annual revenue growth rate through 2029.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44128338/13-analysts-have-this-to-say-about-abbvie">article by Benzinga</a> for 13 analysts' insights on AbbVie.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
<h2 class="wp-block-heading">How Can You Earn $100 Per Month As An AbbVie Investor?</h2>
If you want to make $100 per month — $1,200 annually — from AbbVie dividends, your investment value needs to be approximately $31,088, which is around 183 shares at $170.16 each.&nbsp;
Understanding the dividend yield calculations: When making an estimate, you need two key variables — the desired annual income ($1,200) and the dividend yield (3.86% in this case). So, $1,200 / 0.0386 = $31,088 to generate an income of $100 per month.
You can calculate the dividend yield by dividing the annual dividend payments by the current price of the stock.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
The dividend yield can change over time. This is the outcome of fluctuating stock prices and dividend payments on a rolling basis.
For instance, assume a stock that pays $2 as an annual dividend is priced at $50. Its dividend yield would be $2/$50 = 4%. If the stock price rises to $60, the dividend yield drops to 3.33% ($2/$60). A drop in stock price to $40 will have an inverse effect and increase the dividend yield to 5% ($2/$40).
In summary, income-focused investors may find AbbVie stock an attractive option for making a steady income of $100 per month by owning 183 shares of stock.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Personal Finance

ABBV

How Much Would It Take To Earn $100 A Month From AbbVie Stock

A 25% tariff on imported cars is revving up the pressure on European luxury automakers, and high-end buyers in the U.S. could face five-figure price hikes, according to Tim Urquhart, principal automotive analyst at S&amp;P Global Mobility.
President Donald Trump said on April 10 that his administration would enforce a 25% tariff on imported vehicles as part of his broader &#8220;reciprocal trade&#8221; policy, though he has since suggested he may delay the move.
While some tariffs were delayed for 90 days, this particular levy stayed in place — and it&#8217;s hitting the ultra-luxury market hard.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
<h2 class="wp-block-heading">Ferrari Raises Prices as Other Brands Scramble</h2>
Ferrari <a href="https://www.ferrari.com/en-EN/corporate/articles/ferrari-commercial-policy-update">announced</a> last month that it would increase the prices of nearly all of its models sold in the U.S. by up to 10%. The hike applies even to vehicles ordered months prior, including the newly released Purosangue SUV and the 12 Cilindri grand tourer built in Maranello, Italy.
Urquhart told <a href="https://www.businessinsider.com/trumps-tariffs-threaten-us-love-affair-with-european-luxury-cars-2025-4">Business Insider</a>, "It&#8217;s very bad news. There&#8217;s no getting around that. Ferrari, Bentley, and Rolls-Royce are in a tough spot — they can't absorb a 25% tariff, so that will have to be passed on to customers."
Urquhart added that ultra-luxury brands have more pricing flexibility than mass-market automakers due to their premium sticker prices.
Rolls-Royce, a subsidiary of BMW, is still assessing the situation. <a href="https://www.theguardian.com/business/2025/mar/19/bentley-could-pass-costs-of-us-tariffs-to-buyers-due-to-drop-in-chinese-demand">Bentley</a>, owned by Volkswagen AG, will continue U.S. imports but hasn&#8217;t decided on pricing adjustments.&nbsp;
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
<h2 class="wp-block-heading">Audi, Jaguar, And Mercedes Adjust U.S. Strategies</h2>
Other European automakers are adjusting quickly. <a href="https://media.jaguarlandrover.com/news/2025/04/jlrs-statement-tariffs">Jaguar Land Rover</a> — owned by India's Tata Motors — temporarily halted U.S. shipments to evaluate the impact.&nbsp;
Audi, a Volkswagen subsidiary, was holding deliveries at U.S. ports as it weighed the next steps, according to <a href="https://www.autonews.com/volkswagen/audi/an-trump-tariffs-audi-holds-inventory-0403/">Automotive News</a>.
Mercedes-Benz is also reevaluating its lower-end lineup. As reported by<a href="https://www.bloomberg.com/news/articles/2025-04-01/mercedes-weighs-pulling-us-entry-level-cars-over-trump-tariffs"> Bloomberg</a>, Mercedes may pull some of its entry-level models from the U.S. market due to profitability concerns.
While several automakers posted strong sales gains in March, <a href="https://newsroom.porsche.com/en_US/2025/company/Q1-PCNA-Sales-39125.html">Porsche</a> reported its best-ever first quarter in the U.S., with Q1 2025 sales jumping 40.6%. The company credited strong demand for the 911 and Macan models for the record growth.&nbsp;
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Tariffs Create Long-Term Headaches</h2>
The broader economic fallout could be steep. A report by<a href="https://www.andersoneconomicgroup.com/tariffs-economic-impact-on-auto-industry/"> Anderson Economic Group</a> estimated that U.S. consumers could pay over $30 billion in added costs from the tariffs in the first year alone. The report also mentioned that the average imported vehicle price could climb by $2,500 to $5,000, with ultra-luxury models rising even more.
Strategy and insight director at Cox Automotive, Philip Nothard, told<a href="https://www.businessinsider.com/trumps-tariffs-threaten-us-love-affair-with-european-luxury-cars-2025-4"> Business Insider</a> that shifting production to the U.S. to bypass tariffs would be slow and costly. "You can't just suddenly set up production plants, supply chain, and labor overnight," he said.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Ferrari, Rolls-Royce, And Bentley Prices Are About To Soar As 25% Tariff Sends Shockwaves Through U.S. Luxury Car Market

XFOR

Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending

STSSW

STSS

NAAS

STKH

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 20 years by 6.35% on an annualized basis producing an average annual return of 14.42%. Currently, Eli Lilly has a market capitalization of $797.04 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 20 years ago, it would be worth $15,015.11 today based on a price of $887.40 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745624717_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

$1000 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) has outperformed the market over the past 10 years by 7.94% on an annualized basis producing an average annual return of 18.14%. Currently, Live Nation Entertainment has a market capitalization of $30.51 billion. 
Buying $100 In LYV: If an investor had bought $100 of LYV stock 10 years ago, it would be worth $517.99 today based on a price of $132.00 for LYV at the time of writing.
<h3>Live Nation Entertainment's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745623811_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today

Morningstar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MORN#NASDAQ">MORN</a>) has outperformed the market over the past 20 years by 24.47% on an annualized basis producing an average annual return of 32.54%. Currently, Morningstar has a market capitalization of $12.00 billion. 
Buying $100 In MORN: If an investor had bought $100 of MORN stock 20 years ago, it would be worth $27,993.02 today based on a price of $280.63 for MORN at the time of writing.
<h3>Morningstar's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MORN

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

Grant Cardone does everything he can to minimize his income taxes. The real estate investor and bestselling author moved to Florida to avoid state income taxes, and he also uses various assets to minimize his federal income taxes.
Cardone recently laid out the playbook for reducing your taxable income on paper to keep more of what you earn. However, he started right out of the gate by telling people what they shouldn't do with their money.
"If you can't write it off, don't buy it," Cardone stated in an <a href="https://x.com/GrantCardone/status/1913579678729744714">X post</a>.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>How do billionaires pay less in income tax than you?<a href="https://www.benzinga.com/money/tax-deferring-adv"> Tax deferring is their number one strategy</a>.</li>
</ul>
Anyone can use these strategies to trim their tax burden. While there are more tax-saving tactics you can use if you speak with a professional, Cardone's post offers a head start.
<h2 class="wp-block-heading">Invest In Real Assets And Claim Depreciation&nbsp;</h2>
Cardone's first tip for lowering your taxes was to invest in real assets and claim depreciation. It makes sense that this tip would be on the top of Cardone's list. He has a $5 billion real estate portfolio and regularly looks for new deals.
Real estate investors can use depreciation to artificially reduce their taxable income. However, it gets even better for investors who regularly buy properties and use Section 179 of the tax code. This part of the tax code allows an investor to write off an entire property's value in one year. For instance, if an investor earns $1 million and buys a $1.5 million property, they can show a $500,000 net loss when they report to the IRS.
Trending: It&#8217;s no wonder Jeff Bezos holds over $250 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
You have to fulfill certain conditions to be eligible for Section 179 of the tax code. However, if you're eligible, you can save a lot of money while investing in real assets. This tax strategy also works with any vehicle that is more than 6,000 pounds.
<h2 class="wp-block-heading">Buy, Borrow, Die</h2>
Cardone is a fan of the "Buy, Borrow, Die" model, which involves borrowing against assets instead of selling them. Assets can gain value over time, especially inflation hedges like real estate. If you borrow against these assets instead of selling them, you don't have to pay any capital gains taxes. Furthermore, you still get to benefit from any cash flow and appreciation.
As your net worth grows, you get to borrow cash at lower interest rates. Billionaires get lower interest rates than most people because they are the banks' largest customers. As you grow wealth, it becomes cheaper to borrow money. You can gradually pay back debt and still get to keep your assets when it's all said and done.
See Also: Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.
<h2 class="wp-block-heading">Set Up A Home Office</h2>
Business owners and side hustlers can set up home offices and deduct it for tax purposes. It's extra money that the IRS is willing to let you keep as long as you have the right documentation.
Finally, if you're going the business route, you might as well put your kids on payroll. Cardone recommends this strategy because your kids will receive a lower tax rate than you would at your highest dollar. Your children can also take advantage of the standard tax deduction to further reduce how much they pay. Meanwhile, it will show up in your finances as a business expense, which will reduce your taxable income.
Most parents want to give their children inheritances anyway. Setting them up as business employees allows you to give them the money without the government taking some of it away. You also end up with a lower tax bill.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>
Image: Shutterstock

Grant Cardone Reveals How Anyone Can Lower Their Tax Bill: 'If You Can't Write It Off, Don't Buy It'

Corcept Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORT#NASDAQ">CORT</a>) has outperformed the market over the past 10 years by 18.46% on an annualized basis producing an average annual return of 28.66%. Currently, Corcept Therapeutics has a market capitalization of $7.52 billion. 
Buying $1000 In CORT: If an investor had bought $1000 of CORT stock 10 years ago, it would be worth $11,852.89 today based on a price of $71.25 for CORT at the time of writing.
<h3>Corcept Therapeutics's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745622011_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CORT

Here's How Much $1000 Invested In Corcept Therapeutics 10 Years Ago Would Be Worth Today

Modine Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOD#NYSE">MOD</a>) has outperformed the market over the past 15 years by 1.48% on an annualized basis producing an average annual return of 12.15%. Currently, Modine Manufacturing has a market capitalization of $4.27 billion. 
Buying $1000 In MOD: If an investor had bought $1000 of MOD stock 15 years ago, it would be worth $5,790.86 today based on a price of $81.13 for MOD at the time of writing.
<h3>Modine Manufacturing's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745621111_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Shaquille O'Neal's life isn't divided by status—it's defined by impact. One minute he's fielding calls from billionaires, the next he's helping a <a href="https://www.benzinga.com/personal-finance/25/01/42953411/nba-star-shaq-learned-true-meaning-of-pressure-after-his-dad-took-him-to-a-homeless-family-he-paid-36000-to-get-them-off-the-streets">homeless family get an apartment</a>.&nbsp;
In 2017, he announced plans to run for sheriff in 2020 to <a href="https://youtu.be/GlhvMjeSg-c?si=hH1qoWxL2ECl8ZUU">WXIA-TV Atlanta</a>, stating, "This is not about politics. This is about bringing people closer together." Though he never officially filed, the sentiment reflected his lifelong commitment to community and connection.
"I'm a guy that speaks all languages," Shaq explained. "I can put on a suit and have a conversation with Bill Gates. I can go in the hood and talk to the homies, and talk to the children."
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
</ul>
This philosophy has guided his ventures beyond basketball. A chance encounter at a hotel led to an early investment in Google. While dining at the Four Seasons, <a href="https://www.benzinga.com/personal-finance/24/10/41432168/nba-icon-shaquille-oneal-says-an-accidental-babysitting-gig-led-to-his-early-investment-in-googl">Shaq played with some children</a> whose father, impressed by his demeanor, offered him an investment opportunity in a then-little-known company called Google. Shaq invested and later remarked on "The Ellen DeGeneres Show," "I got a really big return."&nbsp;
His investment strategy was influenced by <a href="https://www.benzinga.com/personal-finance/25/03/44068159/nba-legend-shaq-says-his-net-worth-quadrupled-once-he-took-note-from-jeff-bezos-and-started-investing-in-things-that-change-peoples-lives">Jeff Bezos's advice to invest in things that change people's lives</a>. This approach led Shaq to invest in companies like Ring and Lyft, leveraging his celebrity status to gain early access to promising ventures.&nbsp;
However, not all his business decisions were hits. He passed on investing in Starbucks, believing at the time that "Black people don't drink coffee." He later admitted this was one of his biggest business regrets.
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
Shaq's commitment to authenticity is evident in his business choices. He sold his <a href="https://www.benzinga.com/startups/24/12/42468734/nba-legend-shaq-owned-17-auntie-annes-franchises-but-sold-them-after-realizing-black-people-dont-like-pretzels-that-much">17 Auntie Anne's pretzel franchises</a>, explaining on the "<a href="https://youtu.be/XByJpQzl2DY?si=-dFFd6BsJFCji1ot">Earn Your Leisure Podcast</a>," "Black people don't like pretzels that much. So I had to switch it up."
But the missteps don't outshine the bigger picture. He buys laptops for kids he just met. Pays for strangers' funerals. Picks up the tab for young fans <a href="https://www.benzinga.com/personal-finance/25/01/43077262/nba-legend-shaq-spotted-a-young-man-buying-an-engagement-ring-in-zales-when-he-swooped-in-and-paid-for-it-tell-your-girlfriend-i-got-it">buying engagement rings</a>. And he never posts about it—he lets the people on the receiving end do the talking.
In 2021, his <a href="https://www.benzinga.com/personal-finance/25/03/44207096/shaq-said-his-krispy-kreme-store-was-likely-burned-down-by-homeless-trying-to-stay-warm-im-not-gonna-be-putting-charges-on-homeless-people">Krispy Kreme store in Atlanta was destroyed by fire</a> for a second time, Shaq didn't flinch. Authorities believed homeless individuals had started the blaze trying to stay warm. He chose not to press charges.
Shaq may not have become sheriff like he once hoped, <a href="https://www.benzinga.com/personal-finance/25/03/44380108/trust-me-im-reading-what-hes-doing-every-day-nba-legend-shaq-with-a-500-million-net-worth-swears-by-warren-buffetts-investing-wisdom">but with a $500 million net worth</a> and a reputation built on real connection, he hardly needed the badge. When he says he can talk business with Gates and friends from the "hood"—he means it. And that range? That's not a gimmick. It's why people trust him, invest with him, and invite him into conversations that actually move things forward.
Read Next:
<ul>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.60 per share now</a>.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>
Photo: Shutterstock

NBA Legend Shaq Says He Can 'Throw On a Suit And Have A Conversation With Bill Gates' Then Head to the Hood and Talk to the 'Homies'

Moodys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCO#NYSE">MCO</a>) has outperformed the market over the past 20 years by 4.45% on an annualized basis producing an average annual return of 12.52%. Currently, Moodys has a market capitalization of $78.92 billion. 
Buying $100 In MCO: If an investor had bought $100 of MCO stock 20 years ago, it would be worth $1,065.00 today based on a price of $438.62 for MCO at the time of writing.
<h3>Moodys's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745620214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Moodys 20 Years Ago Would Be Worth This Much Today

Liberty Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LBRT#NYSE">LBRT</a>) has outperformed the market over the past 5 years by 13.64% on an annualized basis producing an average annual return of 27.66%. Currently, Liberty Energy has a market capitalization of $1.97 billion. 
Buying $100 In LBRT: If an investor had bought $100 of LBRT stock 5 years ago, it would be worth $368.79 today based on a price of $12.16 for LBRT at the time of writing.
<h3>Liberty Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745619310_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LBRT

Here's How Much You Would Have Made Owning Liberty Energy Stock In The Last 5 Years

Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) reported quarterly earnings of $1.19 per share which beat the analyst consensus estimate of $1.09 by 9.17 percent. This is a 30.77 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $3.12 billion which beat the analyst consensus estimate of $2.96 billion by 5.51 percent. This is a 20.08 percent increase over sales of $2.60 billion the same period last year.

Earnings Beats

SCCO

Southern Copper Q1 EPS $1.19 Beats $1.09 Estimate, Sales $3.12B Beat $2.96B Estimate

Coca-Cola Femsa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KOF#NYSE">KOF</a>) reported quarterly earnings of $1.20 per share which missed the analyst consensus estimate of $1.37 by 12.41 percent. This is a 14.29 percent decrease over earnings of $1.40 per share from the same period last year. The company reported quarterly sales of $3.43 billion which missed the analyst consensus estimate of $3.45 billion by 0.52 percent. This is a 8.70 percent decrease over sales of $3.76 billion the same period last year.

Earnings Misses

Coca-Cola Femsa Q1 EPS $1.20 Misses $1.37 Estimate, Sales $3.43B Miss $3.45B Estimate

Throughout the last three months, 13 analysts have evaluated Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">3</td>
<td align="right">3</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">2</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $36.85, a high estimate of $68.00, and a low estimate of $21.00. This upward trend is apparent, with the current average reflecting a 32.7% increase from the previous average price target of $27.77.
<img src="https://www.benzinga.com/files/images/story/2025/1745618458_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Hims &amp; Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Lowers &#x7C;Sell &#x7C; $25.00&#x7C;$27.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Lowers &#x7C;Hold &#x7C; $33.00&#x7C;$39.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $22.00&#x7C;$21.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Maintains &#x7C;Underperform &#x7C; $21.00&#x7C;$21.00 &#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Maintains &#x7C;Sell &#x7C; $27.00&#x7C;$27.00 &#x7C; 
&#x7C;Jailendra Singh &#x7C;Truist Securities &#x7C;Raises &#x7C;Hold &#x7C; $39.00&#x7C;$24.00 &#x7C; 
&#x7C;Michael Cherny &#x7C;Leerink Partners &#x7C;Raises &#x7C;Market Perform &#x7C; $40.00&#x7C;$24.00 &#x7C; 
&#x7C;Korinne Wolfmeyer &#x7C;Piper Sandler &#x7C;Raises &#x7C;Neutral &#x7C; $35.00&#x7C;$24.00 &#x7C; 
&#x7C;Ryan MacDonald &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $61.00&#x7C;$31.00 &#x7C; 
&#x7C;Daniel Grosslight &#x7C;Citigroup &#x7C;Raises &#x7C;Sell &#x7C; $27.00&#x7C;$25.00 &#x7C; 
&#x7C;Allen Lutz &#x7C;B of A Securities &#x7C;Raises &#x7C;Underperform &#x7C; $21.00&#x7C;$18.00 &#x7C; 
&#x7C;Maria Ripps &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $68.00&#x7C;$38.00 &#x7C; 
&#x7C;Craig Hettenbach &#x7C;Morgan Stanley &#x7C;Raises &#x7C;Equal-Weight &#x7C; $60.00&#x7C;$42.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Hims &amp; Hers Health. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Hims &amp; Hers Health compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Hims &amp; Hers Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Hims &amp; Hers Health's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/HIMS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Hims &amp; Hers Health analyst ratings.</a>
<h2>All You Need to Know About Hims &amp; Hers Health</h2>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
<h3>Understanding the Numbers: Hims &amp; Hers Health's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Hims &amp; Hers Health's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 95.09%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Hims &amp; Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 5.41%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims &amp; Hers Health's ROE stands out, surpassing industry averages. With an impressive ROE of 5.68%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Hims &amp; Hers Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.97% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Hims &amp; Hers Health's debt-to-equity ratio is below the industry average. With a ratio of 0.02, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Breaking Down Hims & Hers Health: 13 Analysts Share Their Views

Throughout the last three months, 17 analysts have evaluated Merit Medical Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMSI#NASDAQ">MMSI</a>), offering a diverse set of opinions from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Merit Medical Systems, revealing an average target of $114.12, a high estimate of $128.00, and a low estimate of $100.00. Observing a downward trend, the current average is 2.51% lower than the prior average price target of $117.06. 
<img src="https://www.benzinga.com/files/images/story/2025/1745618451_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Merit Medical Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $108.00&#x7C;$127.00 &#x7C; 
&#x7C;Jayson Bedford &#x7C;Raymond James &#x7C;Lowers &#x7C;Outperform &#x7C; $108.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $103.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $100.00&#x7C;$116.00 &#x7C; 
&#x7C;David Rescott &#x7C;Baird &#x7C;Lowers &#x7C;Outperform &#x7C; $110.00&#x7C;$111.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $112.00&#x7C;$116.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Maintains &#x7C;Outperform &#x7C; $111.00&#x7C;$111.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Maintains &#x7C;Buy &#x7C; $116.00&#x7C;$116.00 &#x7C; 
&#x7C;Robbie Marcus &#x7C;JP Morgan &#x7C;Announces &#x7C;Overweight &#x7C; $120.00&#x7C;- &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Lowers &#x7C;Outperform &#x7C; $111.00&#x7C;$115.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Lowers &#x7C;Buy &#x7C; $127.00&#x7C;$128.00 &#x7C; 
&#x7C;Larry Biegelsen &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $117.00&#x7C;$120.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Lowers &#x7C;Buy &#x7C; $116.00&#x7C;$122.00 &#x7C; 
&#x7C;Jason Bednar &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $116.00&#x7C;$114.00 &#x7C; 
&#x7C;Michael Petusky &#x7C;Barrington Research &#x7C;Raises &#x7C;Outperform &#x7C; $115.00&#x7C;$114.00 &#x7C; 
&#x7C;Jon Young &#x7C;Canaccord Genuity &#x7C;Raises &#x7C;Buy &#x7C; $128.00&#x7C;$127.00 &#x7C; 
&#x7C;Mike Matson &#x7C;Needham &#x7C;Raises &#x7C;Buy &#x7C; $122.00&#x7C;$109.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Merit Medical Systems. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Merit Medical Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Merit Medical Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Merit Medical Systems's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MMSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Merit Medical Systems analyst ratings.</a>
<h2>Discovering Merit Medical Systems: A Closer Look</h2>
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices.
<h3>Merit Medical Systems's Financial Performance</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Revenue Growth: Merit Medical Systems displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 9.44%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Merit Medical Systems's net margin is impressive, surpassing industry averages. With a net margin of 7.87%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Merit Medical Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 2.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.17%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.58, Merit Medical Systems adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

MMSI

The Analyst Verdict: Merit Medical Systems In The Eyes Of 17 Experts

Press Releases

Truist to speak at the RBC Capital Markets Global Financial Institutions Conference

Truist strengthens middle market banking team in New Jersey

Truist announces first-quarter 2025 earnings call details

Fintech

Truist Securities strengthens its biotech equity research coverage

Truist names Claudia Davis Adamson as head of small business banking

Truist Foundation announces six finalists for third Inspire Awards

Contracts

Sheffield Financial and Polaris extend multi-year retail financing partnership

Truist reports first quarter 2025 results

Truist Securities enhances Industrials and Services expertise

Truist first bank to begin revolutionizing bill pay with alias-based request for payment via the RTP® network

BOK Financial

Cadence Bank

Commerce Bancshares

Citizens Financial Group, Inc. Common Stock

Citizens Financial Group

Cullen/Frost Bankers

Columbia Banking System, Inc. - Common Stock

Columbia Banking System

East West Bancorp

First Horizon

Huntington Bancshares Incorporated - Common Stock

Huntington Bancshares

Home BancShares

M&T Bank

Old National

Prosperity Bancshares

Pinnacle Financial Partners, Inc. - Common Stock

Pinnacle Finl Partners

Regions Financial Corporation Common Stock

Regions Finl

Synovus Financial

SouthState

United Bankshares

UMB Financial

Valley Ntl

Western Alliance Bancorporation Common Stock (DE)

Western Alliance

Webster Financial Corporation Common Stock

Webster Financial

Wintrust Financial Corporation - Common Stock

Wintrust Financial

Zions Bancorp

Keefe, Bruyette & Woods

Stephens & Co.

Barclays

Piper Sandler

Morgan Stanley

Truist Financial

지역 은행 부문은 지난 2년 동안 잘못된 이유로 많은 헤드라인을 장식했다. 실리콘밸리 은행, 시그니처 은행 및 퍼스트 리퍼블릭 은행과 같은 <a href="https://www.fdic.gov/resources/resolutions/bank-failures/in-brief/2023" target="_blank" rel="noopener">은행 파산</a> 사건은 이 부문에 큰 충격을 주었고, 2023년 말 SPDR 지역은행 ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>)는 40% 이상 하락했다.
2024년 초에도 또 다른 두 건의 실패 사건이 발생한 후 투자자들은 긴장 상태를 유지했지만, 연방준비제도(연준)의 금리 인하 전략과 2024년 미국 대통령 선거 결과에 따라 이 부문은 반등했다.
트럼프 행정부의 출범은 린다 칸(연방거래위원회, FTC), 로힛 초프라(소비자금융보호국, CFPB) 그리고 개리 겐슬러(증권거래위원회, SEC) 등 여러 주요 규제 당국을 교체할 것으로 예상되며, 이는 규제를 완화하여 인수합병을 더 용이하게 할 수 있는 분위기를 조성할 수 있다.
지역 은행들은 이러한 태도 변화의 최대 수혜자가 될 가능성이 높으며, KRE는 이미 지난 한 달 동안 18% 상승했다.
새로운 규제 당국이 들어서기 전에 사야 할 가장 유망한 지역 은행 주식 5종목을 살펴보겠다.
<h2 class="wp-block-heading">어떻게 6종목을 선별했는가?</h2>
자본 기준 완화와 규제 심사의 완화는 금융 부문에 많은 기업들에게 이익이 될 것이다. 우리는 다음 기준에 따라 지역 은행 주식 리스트를 5개로 압축했다:
<ul>
<li>규제 완화의 수혜자 &#8211; 트럼프 행정부 2기 동안 자본 요건(바젤 III와 같은)과 유동성 기준을 완화하고 인수합병 환경을 우호적으로 만들 수 있다. 지역 은행은 이러한 요건을 대형 국책 은행보다 효율적으로 충족할 수 없기 때문에 규제 완화는 종종 소형 은행에 유리하다.</li>
<li>평가 지표 &#8211; 우리 리스트에 있는 은행들은 동종 업계의 동료들에 비해 저렴한 주가를 보이고 있으며, 주가수익비율(P/E), 주가매출비율(P/S) 및 주가순자산비율(P/B) 등의 지표를 기준으로 한다.</li>
<li>배당 수익률 &#8211; 은행 주식을 보유하고 있다면 주가 상승과 배당 소득으로 보상을 받고 싶다. 이 지역 은행들은 모두 업계 평균보다 높은 배당 수익률을 제공한다.</li>
</ul>
<h2 class="wp-block-heading">구매할 지역 은행 6종목</h2>
위의 기준에 따라, 트럼프 행정부 2기와 새로운 규제 당국이 워싱턴에 들어서기 전에 포트폴리오에 추가할 것을 고려할 수 있는 5개 지역 은행 주식이 있다.
<h3 class="wp-block-heading">US 뱅코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>)</h3>
US 뱅코프의 뿌리는 남북전쟁 시기로 거슬러 올라가며, 미국의 24번째 국립은행 허가를 받았다. 오늘날 이 은행은 830억 달러 이상의 시장 가치를 지니고 있으며, 68,000명의 직원을 둔 미국 최대의 지역 은행 중 하나이다. USB 주식은 2024년 동안 23%의 연초 대비 상승률을 기록하며 KRE의 30% 상승률보다 뒤처졌지만, 규제가 완화되면 2022년에 <a href="https://www.usbank.com/about-us-bank/company-blog/article-library/us-bancorp-completes-acquisition-of-union-bank.html" target="_blank" rel="noopener">MUFG 유니언 뱅크를 인수</a>하여 캘리포니아, 오리건 및 워싱턴으로 운영을 확장한 은행에 긍정적인 영향을 미칠 수 있다. 이 주식은 16.5의 P/E 비율과 1.97의 P/S 비율과 같은 합리적인 기본 지표를 가지며, 3.73%의 배당 수익률을 제공한다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-670667" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-1024x395.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133051/USB.png 1364w" alt="" width="1024" height="395" /></figure>
<h3 class="wp-block-heading">키코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>)</h3>
키코프는 시가총액이 200억 달러 이하이며 US 뱅코프와 같은 대형 지역 은행보다 영향력이 적지만, 주식은 가치, 높은 배당 수익률 및 규제 완화로 인한 잠재적 성장의 조합 덕분에 우리 리스트에 올라왔다. 이 은행은 소비자 은행과 상업 은행의 두 가지 부문으로 나뉘며, 상업 부문은 중소기업 서비스에 초점을 맞추고 있다. 키뱅크 캐피털 마켓(KeyBanc Capital Markets)는 중소기업 인수합병(M&amp;A) 시장에서 500개 이상의 고객과 협상한 M&amp;A 전문 기관이다. KEY 주식은 리스트에 있는 은행 중 가장 높은 P/E 비율인 19.4를 기록하지만, 주주들에게는 4.17%의 배당 수익률을 제공하며, P/B 비율은 업계 하위 3분의 1인 1.3이다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-670668" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-1024x395.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133059/KEY.png 1364w" alt="" width="1024" height="395" /></figure>
<h3 class="wp-block-heading">리전스 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>)</h3>
리전스 파이낸셜은 US 뱅코프나 키코프와 같이 100년 이상의 역사를 가지고 있지는 않지만, 남부 지역의 고객들에게 다양한 은행 및 자산 관리 서비스를 제공합니다. RF 주식은 실제로 2024년 동안 KRE를 초과하는 성과를 보였으며(42% 대 30%), 부채/자본 비율이 0.35로 우리 선택지 중 가장 낮아 잘 자본화된 은행임을 나타내어 더 많은 위험 감수를 통해 이익을 볼 수 있다. 이 주식은 3.66%의 배당 수익률을 제공하며, 13.4의 P/E 비율과 1.48의 P/B 비율을 가지고 있다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-670669" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-1024x395.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133104/RF.png 1364w" alt="" width="1024" height="395" /></figure>
<h3 class="wp-block-heading">트루이스트 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>)</h3>
선트러스트 뱅크(SunTrust Bank)와 BB&amp;T 코퍼레이션의 합병으로 형성된 트루이스트 파이낸셜(Truist Financial)은 우리 리스트에서 두 번째로 큰 지역 은행이며, KRE가 올해 30% 이상 상승한 이유 중 하나이다. TFC 주식은 2024년 동안 지역 은행 ETF 성과와 거의 동일한 수준으로 상승했지만, 주식은 2022년 사상 최고가에는 한참 못 미치고 있다. 트루이스트는 우리 리스트에서 가장 낮은 P/B 비율인 1.08을 기록하며, 4.36%의 배당 수익률을 제공하며 최근에는 보험 및 자산 관리 자회사를 매각하여 유동성과 자본 상황을 개선했다. 트루이스트는 주로 미시시피 강 동쪽의 주들을 서비스하지만, 선벨트 지역으로 운영을 확장할 계획이다. 이러한 계획은 향후 몇 년 동안 인수합병 활동 증가와 규제 완화의 혜택을 받을 수 있다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-670670" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-1024x395.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133110/TFC.png 1364w" alt="" width="1024" height="395" /></figure>
<h3 class="wp-block-heading">M&amp;T 뱅크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>)</h3>
M&amp;T 뱅크(제조업체 및 거래업체 은행)는 1856년까지 거슬러 올라가는 역사를 가진 미국의 가장 오래된 은행 중 하나이다. MTB는 360억 달러의 시장 가치를 가지고 있으며, 2.45%의 배당금을 지급하는데, 이는 리스트에서 가장 낮지만 회사의 수익으로 쉽게 유지될 수 있다. 이 주식은 2024년의 가장 큰 성공 사례 중 하나로, 2024년에 60%라는 놀라운 상승률을 기록하여 지역 은행 ETF의 두 배를 기록했다. 은행의 10월 실적 발표 이후 추가 상승이 있을 수 있으며, 이는 많은 분석가들이 평가와 목표 주가를 상향 조정하게 만들 수 있다. M&amp;T 뱅크는 16.3의 P/E 비율과 1.4의 P/B 비율을 기록하였고, 18.7의 순이익률은 리전스 파이낸셜에만 뒤쳐졌다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-670671" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-1024x395.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133115/MTB.png 1364w" alt="" width="1024" height="395" /></figure>
<h3 class="wp-block-heading">디스커버 파이낸셜 서비스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>)</h3>
디스커버 파이낸셜 서비스는 캐피털 원(Capital One)과 연결되어 있으며, 후자가 전자를 350억 달러에 인수하겠다고 발표한 이후로 거래가 중단되었다. 그러나 뉴욕 규제 당국이 인수합병을 반독점 위반으로 조사하기 시작하면서 거래는 정체되었다. DFS 주식은 7월부터 선거 주간까지 좁은 범위에서 거래되었지만, 트럼프의 승리 다음 날 수요일에 DFS와 COF 주식이 모두 즉시 상승했다. 투자자들은 규제 환경이 완화되면 거래가 성사될 것으로 예상하고 있어, DFS 주식은 앞으로 몇 주 동안 계속 상승할 가능성이 있다.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-670672" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-1024x395.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-1024x395.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-300x116.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS-768x296.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/29133121/DFS.png 1364w" alt="" width="1024" height="395" /></figure>
캠페인 공약이 항상 현실로 이어지지는 않으며, 이전 트럼프 행정부는 종종 말로만 그치는 경우도 있었음을 명심하세요. 규제 완화와 인수합병(M&amp;A)이 예상되지만, 정치적 발언에 기반한 투자들은 본질적으로 단기 투자입니다. 예상과 다른 규제 환경이 나오면 손실 주식은 매각해야 합니다.
2024년, 매트 말리(Matt Maley)의 회원들은 TLT에서 24시간 안에 570%, GDX에서 1주일 만에 460%의 수익을 올릴 수 있는 기회를 가졌으며, 하루에 5건의 수익 거래를 경험했습니다. 이번 블랙프라이데이에 1000달러를 절약하고 월스트리트 전설과 함께 실시간 알림 및 검증된 전략으로 거래하세요. <a href="https://www.benzinga.com/premium/ideas/matt-options-inner-circle-checkout-black-friday/?utm_source=WebRD-1129">여기를 클릭하여 시작하세요.</a>
이미지 출처: Midjourney
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

미국 은행들의 3분기 실적 발표 시즌이 이번 금요일에 공식적으로 시작된다. JP모건 체이스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), 웰스 파고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>) 및 뉴욕 멜론 은행(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>)과 같은 주요 금융 기관들이 <a href="https://www.benzinga.com/news/earnings/24/10/41216873/us-banks-earnings-preview-soft-landing-hopes-interest-rate-cuts-key-catalysts-for-stocks">실적을 발표할 예정</a>이다.
다음 주 화요일에는 뱅크 오브 아메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>), 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) 그리고 씨티그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)과 같은 대형 은행들의 추가적인 실적 발표가 있을 예정이며, 일부 지역 은행들도 포함된다.
<h3 class="wp-block-heading">2024년 현재 은행 부문 성과</h3>
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" class="wp-image-587909" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09104754/image-66-1024x447.png" sizes="(max-width: 1024px) 100vw, 1024px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09104754/image-66-1024x447.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09104755/image-66-300x131.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09104755/image-66-768x336.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09104755/image-66-1536x671.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/09104754/image-66.png 1920w" alt="" width="1024" height="447" /><figcaption class="wp-element-caption">차트: <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent100924&amp;t=be2bearmibe3na1">Benzinga Pro</a></figcaption></figure>
2024년 현재까지 은행 부문은 강력한 성과를 보이고 있다. 주요 금융 주식을 추적하는 Financial Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)는 연초 대비 21% 상승하였으며, 이는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)로 대표되는 전체 시장의 성과와 일치한다.
하지만 지역 은행들은 대형 은행들에 비해 뒤처졌다. SPDR S&amp;P Regional Banking ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>)는 연초 대비 6.7% 상승에 그쳤으나, 최근 3개월 동안은 더 나은 성과를 보였다. 이 최근의 반등은 인플레이션 하락과 연방준비제도(연준)의 금리 인하 기대 증가에 주로 기인한다.
실적 발표 시즌을 맞아 많은 투자자들은 대형 은행들이 지역 은행들에 대한 긍정적인 성과 차이를 유지할 것인지, 아니면 최근의 시장 발전이 그들의 실적과 전망에 영향을 미칠 것인지에 대한 질문을 가지고 있다.
다음은 은행 실적 발표 시즌을 앞두고 월스트리트 애널리스트들이 말하는 내용이다.
<h3 class="wp-block-heading">애널리스트들의 기대와 추천 종목</h3>
<h4 class="wp-block-heading">RBC 캐피털 마켓 – 제럴드 캐시디(Gerard Cassidy), 글로벌 금융 연구 공동 책임자</h4>
&#8220;우리는 향후 12-18개월 동안 은행에 대한 전망이 매우 좋다고 생각한다. 우리는 연준이 이 기간 동안 단기 금리를 200-250bp(베이시스 포인트) 인하할 것으로 예상하며, 바젤 III &#8216;엔드게임&#8217; 제안의 최종화가 은행들이 잉여 자본을 자사주 매입과 배당으로 환원할 수 있게 할 것이다. 우리는 은행 주식에 대한 비중 확대를 지속적으로 추천한다.&#8221;
<ul>
<li>추천 종목 (RBC는 3분기 대해 모두 애널리스트들의 컨센서스를 상회하는 주당순이익(EPS) 추정치를 보유하고 있다.)
<ul>
<li>트루이스트 파이낸셜 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>)</li>
<li>키코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>)</li>
</ul>
</li>
</ul>
<h4 class="wp-block-heading">JP모건 체이스 – 안토니 엘리(Anthony Elian), CFA</h4>
&#8220;연준 금리를 인하함에 따라 여러 산업의 역풍이 순풍으로 전환될 수 있다.&#8221; 여기에는 다음이 포함다:
<ol>
<li>예금 비용 감소, 순이자 마진(NIM) 개선</li>
<li>상업 대출 수요 증가</li>
<li>상업용 부동산(CRE) 노출이 있는 은행에 대한 신용 품질 우려 완화</li>
<li>준비금이 방출되어 자사주 매입 프로그램 재개</li>
<li>인수 시장과 벤처 캐피탈 활동 증가</li>
</ol>
<ul>
<li>추천 종목:
<ul>
<li>퍼스트 시티즌스 뱅크셰어스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NYSE">FCNCA</a>)</li>
<li>웨스턴 얼라이언스 뱅코퍼레이션 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>)</li>
<li>피나클 파이낸셜 파트너스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>)</li>
</ul>
</li>
</ul>
<h4 class="wp-block-heading">웨드부시 증권 – 데이비드 J. 치아베리니(David J. Chiaverini), CFA</h4>
&#8220;우리는 3분기 동안 은행의 혼재된 추세를 예상하며, 대출 및 예금의 완만한 성장, 예금 혼합 변화의 안정화, 고정 자산 재가격으로 인한 NIM 개선을 기대한다. 이 환경에서 일부 은행들이 더 긍정적인 위치에 있을 것이다.&#8221;
<ul>
<li>추천 종목:
<ul>
<li>M&amp;T 뱅크 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>)</li>
<li>윈트러스트 파이낸셜 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTFC#NASDAQ">WTFC</a>)</li>
<li>컬럼비아 뱅킹 시스템 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) 
웨드부시는 컬럼비아 뱅킹 시스템이 부채 민감성으로 인해 낮은 금리 환경에서 혜택을 받을 것이라고 믿고 있다. 대부분의 은행들은 자산 민감성이다.</li>
</ul>
</li>
</ul>
<h4 class="wp-block-heading">뱅크 오브 아메리카 – 에브라힘 푸나왈라(Ebrahim H. Poonawala)</h4>
&#8220;우리는 3분기 실적 발표를 앞두고 대형 머니 센터보다 지역 은행을 선호한다. 이는 순이자수익(NII)의 방어력과 채권 보유의 시장가치 손실 감소로 인한 자본 완화가 더 크기 때문이다. 3분기 실적을 앞두고 우리의 주요 아이디어는 지역 은행들과 대형 금융 기관들의 혼합이다.&#8221;
<ul>
<li>추천 종목:
<ul>
<li>U.S. 뱅코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>)</li>
<li>웨스턴 얼라이언스 뱅코퍼레이션</li>
<li>PNC 파이낸셜 서비스 그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>)</li>
<li>피프스 서드 뱅코프 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NYSE">FITB</a>)</li>
<li>M&amp;T 뱅크</li>
<li>트루이스트 파이낸셜</li>
<li>모건 스탠리 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</li>
<li>골드만삭</li>
<li>뉴욕 멜론 은행</li>
</ul>
</li>
</ul>
<h4 class="wp-block-heading">골드만삭스 – 리처드 램스든(Richard Ramsden)</h4>
골드만삭스는 씨티그룹에 대해 3분기 실적을 앞두고 특히 낙관적이다. 이는 은행이 2024년 목표를 향한 진전을 강력한 수수료 성장, 탄탄한 자본 시장 활동 및 견고한 카드 거래량에 의해 추진되고 있기 때문이다.
램스든은 씨티그룹의 3분기 전 대손충당 전 순수익(PPNR)에 대해 컨센서스를 상회하는 전망을 제시하고 있으며, 이는 주로 더 높은 수수료와 자본 시장 활동에 대한 기대 때문이다.
<ul>
<li>추천 종목:
<ul>
<li>씨티그룹 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</li>
</ul>
</li>
</ul>
다음 읽어보기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/sp-500-%EC%8B%A4%EC%A0%81-%EC%8B%9C%EC%A6%8C-%EC%8B%9C%EC%9E%91-%EC%99%9C-%EB%B6%84%EC%84%9D%EA%B0%80%EB%93%A4%EC%9D%80-%EC%9D%B4%EB%B2%88-%EB%B6%84%EA%B8%B0%EB%A5%BC-%EC%A3%BC%EC%8B%9D/" target="_blank" rel="noopener">S&amp;P 500 실적 발표 시즌 시작: 왜 애널리스트들이 이번 분기를 &#8216;주식 선택자의 천국&#8217;이라고 부르는가?</a></li>
</ul>
이미지는 인공지능 미드저니를 통해 생성되었습니다.

미국 은행들이 3분기 실적을 발표할 준비를 하면서, 투자자들은 경제의 연착륙 가능성, 연방준비제도(연준)의 금리 인하, 그리고 이들이 <a href="https://www.benzinga.com/topic/banks" target="_blank" rel="noopener" data-google-interstitial="false">은행 가치 평가에 미치는 영향</a>에 주목하고 있다.
뱅크 오브 아메리카(Bank of America)의 애널리스트들은 은행 주식 전망에 대해 조심스러운 낙관을 유지하고 있다. 그들은 연착륙 시나리오가 고객 활동의 반등을 촉발하고, 대출 성장을 개선하며 그리고 섹터의 주가수익비율(P/E) 배수를 긍정적으로 유도할 수 있다고 예측한다. 하지만 연준의 정책 변화와 다가오는 미국 선거와 같은 거시적 불확실성이 이 같은 기대를 완화하고 있다.
뱅크 오브 아메리카의 주식 애널리스트인 에브라힘 푸나왈라(Ebrahim H. Poonawala)는 월요일 노트에서 금리 인하가 은행 주당순이익(EPS) 전망과 주식 P/E 배율에 대해 &#8220;구조적으로 긍정적&#8221;일 수 있다고 강조했다. 금리가 낮아지면 고객 활동이 재활성화될 것으로 예상되며, 특히 투자은행, 주택담보대출 및 대출 성장에 긍정적인 영향을 미칠 것이다.
그러나 낮은 금리는 &#8220;자산에 민감한 은행&#8221;에 부정적인 영향을 미칠 것으로 예상되며, 대출 수익률이 하락할 것이다.
추가 읽기: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41212796/tesla-robotaxi-day-preview-move-over-autonomous-vehicles-analyst-says-this-positive">테슬라 로보택시 데이 미리보기: 자율주행차를 제치고, 애널리스트가 말하는 이 &#8216;긍정적 촉매&#8217;가 더 중요할 수 있다</a>
<h3 class="wp-block-heading">정치적 리스크가 대선을 앞두고 크게 작용</h3>
다가오는 미국 선거는 은행들에게 추가적인 불확실성을 더하고 있다.
&#8220;트럼프의 승리는 규제/M&amp;A 분야에서의 완화로 긍정적으로 작용할 가능성이 높다. 민주당의 압승은 높은 세금, 규제 변화의 지속(또는 악화) 가능성 때문에 섹터에 가장 부정적인 결과로 작용할 가능성이 높다&#8221;라고 애널리스트들이 언급했다.
현재의 가치 평가가 연착륙에 대해 조심스레 낙관적인 모습을 보이고 있지만, 정치적 결과는 섹터에 변동성을 유발할 수 있다. 트럼프가 승리하면 은행 주식은 &#8220;즉각적인&#8221; 긍정적인 반응을 보일 가능성이 높고, 민주당이 승리하면 투자 심리에 부정적인 영향을 미칠 수 있다.
<h3 class="wp-block-heading">지역 은행이 메인스트리트 은행보다 선호됨</h3>
2024년 3분기에 이 투자 은행은 SPDR S&amp;P Regional Banking ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRE#NYSE">KRE</a>)에서 추적하는 바와 같이 대형 머니 센터 은행들보다 &#8220;순이자 소득(NII)에 대한 더 나은 방어력&#8221;을 이유로 지역 은행들을 선호했다.
지역 은행들은 예금에 대한 더 큰 유연성, 더 나은 헤징 전략, 그리고 채권 평가손실이 줄어들면서 자본 완화의 가능성이 더 높다.
주요 추천주로는 U.S. 뱅코프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>), 웨스턴 얼라이언스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAL#NYSE">WAL</a>), PNC 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>), 피프스 써드(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>), M&amp;T 뱅크(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>), 그리고 트루이스트 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>)이 있다.
퍼스트 뱅코프(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>)는 &#8220;현재 금리 기대치를 헤쳐나가기 가장 잘 대비된&#8221; 은행으로 평가되었으며, 텍사스 캐피털 뱅크셰어스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBI#NASDAQ">TCBI</a>)는 가장 큰 영향을 받을 것으로 보인다.
월요일, 뱅크 오브 아메리카는 코메리카(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMA#NYSE">CMA</a>)를 &#8220;중립&#8221;에서 &#8220;부진&#8221;으로 하향 조정하고 목표 주가를 55달러에서 52달러로 낮췄다. 애널리스트인 브랜든 버만(Brandon Berman)은 코메리카를 지탱하던 긍정적인 금리 거래가 &#8220;그 과정을 마쳤다&#8221;고 강조하며, 이 주식은 이제 역사적 범위의 상단을 넘어서 거래되고 있어 하향 조정된 실적 전망의 위험을 반영하지 않고 있다고 설명했다.
앞으로, 10월 11일 금요일에는 JP모건 체이스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), 웰스 파고(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>), 그리고 뉴욕 멜론 은행(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNY#NYSE">BNY</a>)의 주요 실적 보고가 있을 것이다.

다음 읽기:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/10/41214476/will-kamala-harriss-media-blitz-including-60-minutes-and-call-her-daddy-improve-her-2024-el">카멀라 해리스의 미디어 공세가 2024년 선거 전망을 개선할 수 있을까요?</a></li>
</ul>
이미지는 인공지능을 사용하여 생성되었습니다.
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

편집자 주: 이 기사에는 연준의 스트레스 테스트 보고서에 언급된 회사인 Citizens Financial Group Inc.가 아닌 Citizens Inc.의 주식 정보가 잘못 포함되어 수정되었습니다.
미국 연방준비제도(연준)의 연례 은행 스트레스 테스트는 수요일에 대형 은행들이 경기 침체 시나리오에서 작년보다 더 큰 예상 손실에 직면하고 있지만, 여전히 심각한 경기 침체를 견디고 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39461418/us-bank-stress-tests-this-week-analyst-expects-improvement-8-stocks-3-etfs-to-watch" target="_blank" rel="noopener" data-google-interstitial="false">최소 자본 요건을 유지</a>할 수 있는 좋은 위치에 있음을 보여준다.
"올해의 스트레스 테스트는 대형 은행들이 매우 스트레스가 큰 시나리오에서도 충분한 자본을 보유하고 최소 자본 비율을 충족할 수 있음을 보여준다"고 연준 감독 부문 부의장인 마이클 S. 바(Michael S. Barr)가 말했다.
올해의 스트레스 테스트 부정적 시나리오는 작년과 마찬가지로 심각하지만, 은행 대차대조표의 약간 더 높은 위험과 증가한 비용 때문에 더 큰 손실이 발생했다고 그가 말했다.
2023년 지역 은행 위기를 회상하며, 바는 중요한 교훈이 얻어졌다고 강조했다.
연준은 &#8220;대형 은행들이 일반적으로 예금 이동의 형태로 갑작스러운 자금 충격을 견딜 수 있는 좋은 위치에 있다&#8221;고 밝혔다. 또한, 자금 충격 가정을 감안하더라도 은행의 순이자 수익은 고금리 환경에서 탄력적으로 유지되고 있다.
<h3 class="wp-block-heading">2024년 은행 스트레스 테스트 세부사항, 결과</h3>
올해 테스트에서는 31개 은행 모두 총 예상 가상 손실이 약 6850억 달러에 달함에도 불구하고 최소 보통주 자본 비율 1(CET1) 요건을 초과했다.
올해의 테스트 가상 시나리오는 작년의 심각한 세계적 경기 침체 테스트와 유사하며, 상업용 부동산 가격이 40% 하락하고, 사무실 공실률이 크게 증가하며, 주택 가격이 36% 하락하는 상황을 포함한다. 실업률은 스트레스 테스트에서 10%로 정점에 달하며 경제 생산량도 이에 따라 감소했다.
이 스트레스 시나리오 하에서, 총 보통주 자본 비율(CET1)은 12.7%에서 9.9%로 2.8 퍼센트 포인트 하락할 것으로 예상된다. 이는 작년 테스트보다 더 큰 하락이지만 최근 테스트 범위 내에 있다.
올해 테스트에서 더 큰 자본 감소에 기여한 세 가지 주요 요인은 다음과 같다:
<ol>
<li>신용카드 손실 증가: 신용카드 잔액의 상당한 증가와 높은 연체율로 인해 예상되는 신용카드 손실이 증가했다. 신용카드 손실에 가장 많이 노출된 은행은 앨리 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLY#NYSE">ALLY</a>), 디스커버 파이낸셜 서비스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) 및 골드만삭스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)이다.</li>
<li>더 위험한 기업 대출 포트폴리오: 은행들은 기업 대출을 다운그레이드하여 리스크가 증가했음을 반영했고, 이로 인해 예상되는 기업 손실도 증가했다. 기업 대출 잔액에 가장 큰 영향을 받을 것으로 예상되는 은행은 디스커버 파이낸셜 서비스, 바클레이즈(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCS#NYSE">BCS</a>) 및 시티즌 파이낸셜 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>)이다.</li>
<li>높은 비용과 낮은 수수료 수익: 비용 증가와 수수료 수익 감소로 인해 예상되는 수익이 줄어들면서 자본 감소가 악화되었다.</li>
</ol>
이러한 예상 손실에는 신용카드 손실 1,750억 달러, 상업 및 산업 대출에서 1,420억 달러, 상업용 부동산에서 770억 달러가 포함된다.
&#8220;대형 은행의 상업용 부동산(CRE) 부채 노출은 연방 준비 제도 이사회 감독관들의 주요 관심사로 남아있다&#8221;고 이 보고서에서 밝혔다.
2024년 감독관의 심각한 악화 시나리오에는 상업용 부동산(CRE) 스트레스 증가가 포함되며, CRE 가격은 40% 하락할 것으로 예상된다.
사무실 부문에서의 악화된 기본 요인으로 인해 사무실 건물 대출에 대한 예상 손실이 증가했지만, 연준은 호텔 및 소매 부동산 대출에 대한 예상 손실이 감소하면서 이러한 손실이 균형을 이루고 있다고 밝혔다. 이는 지난 해 동안 이들 부문의 시장 기본 요인이 개선되었기 때문이다.
시장 반응: 미 동부 시간 오후 5:05 기준 캐피탈 원 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), 시티즌 파이낸셜 그룹(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) 및 골드만삭스는 Financial Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>) 구성 주식들 중 가장 많이 하락했다. 최고의 종목은 1.7% 상승한 트루이스트 파이낸셜(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>)이었다.
지금 읽기: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39506069/yen-plummets-to-160-against-dollar-lowest-since-december-1986-is-bank-of-japan-inte">엔화는 1986년 12월 이후 최저치인 달러 대비 160으로 급락: 일본은행의 개입이 임박?</a>
사진 제공: 셔터스톡

Comments

Truist Finl

뉴스

에 대한 최신 뉴스 Truist Finl (NYSE:TFC) 주식

토요일, 11월 30, 2024

목요일, 10월 10, 2024

월요일, 10월 07, 2024

수요일, 6월 26, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌